Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Biochemical Analyses
2.2. Covariates
2.3. Statistical Analysis
2.4. Additional Analyses
3. Results
3.1. Plasma CRP, CA 19-9, IL-6, YKL-40 and Survival
3.2. Plasma CRP, CA 19-9, IL-6 and YKL-40: Biomarker Score
3.3. Additional Analyses
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014, 74, 2913–2921. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gordon-Dseagu, V.L.; Devesa, S.S.; Goggins, M.; Stolzenberg-Solomon, R. Pancreatic cancer incidence trends: Evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int. J. Epidemiol. 2018, 47, 427–439. [Google Scholar] [CrossRef] [PubMed]
- Kleeff, J.; Korc, M.; Apte, M.; La Vecchia, C.; Johnson, C.D.; Biankin, A.V.; Neale, R.E.; Tempero, M.; Tuveson, D.A.; Hruban, R.H.; et al. Pancreatic cancer. Nat. Rev. Dis. Primers 2016, 2, 16022. [Google Scholar] [CrossRef]
- Crawford, H.C.; Pasca di Magliano, M.; Banerjee, S. Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. Gastroenterology 2019, 156, 2073–2084. [Google Scholar] [CrossRef] [PubMed]
- Babic, A.; Schnure, N.; Neupane, N.P.; Zaman, M.M.; Rifai, N.; Welch, M.W.; Brais, L.K.; Rubinson, D.A.; Morales-Oyarvide, V.; Yuan, C.; et al. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin. Transl. Gastroenterol. 2018, 9, 145. [Google Scholar] [CrossRef]
- Haas, M.; Heinemann, V.; Kullmann, F.; Laubender, R.P.; Klose, C.; Bruns, C.J.; Holdenrieder, S.; Modest, D.P.; Schulz, C.; Boeck, S. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J. Cancer Res. Clin. Oncol. 2013, 139, 681–689. [Google Scholar] [CrossRef]
- Mitsunaga, S.; Ikeda, M.; Shimizu, S.; Ohno, I.; Takahashi, H.; Okuyama, H.; Ueno, H.; Morizane, C.; Kondo, S.; Sakamoto, Y.; et al. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. Pancreas 2016, 45, 110–116. [Google Scholar] [CrossRef]
- Szkandera, J.; Stotz, M.; Absenger, G.; Stojakovic, T.; Samonigg, H.; Kornprat, P.; Schaberl-Moser, R.; Alzoughbi, W.; Lackner, C.; Ress, A.L.; et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br. J. Cancer 2014, 110, 183–188. [Google Scholar] [CrossRef] [Green Version]
- Vainer, N.; Dehlendorff, C.; Johansen, J.S. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget 2018, 9, 29820–29841. [Google Scholar] [CrossRef] [Green Version]
- Xue, P.; Zhu, L.; Wan, Z.; Huang, W.; Li, N.; Chen, D.; Hu, J.; Yang, H.; Wang, L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J. Cancer Res. Clin. Oncol. 2015, 141, 1653–1660. [Google Scholar] [CrossRef] [Green Version]
- Chen, I.M.; Johansen, A.Z.; Dehlendorff, C.; Jensen, B.V.; Bojesen, S.E.; Pfeiffer, P.; Bjerregaard, J.K.; Nielsen, S.E.; Andersen, F.; Hollander, N.H.; et al. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiol. Biomark. Prev. 2020, 29, 176–184. [Google Scholar] [CrossRef] [PubMed]
- Schultz, N.A.; Christensen, I.J.; Werner, J.; Giese, N.; Jensen, B.V.; Larsen, O.; Bjerregaard, J.K.; Pfeiffer, P.; Calatayud, D.; Nielsen, S.E.; et al. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS ONE 2013, 8, e67059. [Google Scholar] [CrossRef]
- Khomiak, A.; Brunner, M.; Kordes, M.; Lindblad, S.; Miksch, R.C.; Öhlund, D.; Regel, I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers 2020, 12, 3234. [Google Scholar] [CrossRef]
- Nurmi, A.M.; Mustonen, H.K.; Stenman, U.H.; Seppänen, H.E.; Haglund, C.H. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma. Sci. Rep. 2021, 11, 781. [Google Scholar] [CrossRef]
- Chen, I.; Vittrup Jensen, B.; Bojesen, S.E.; Johansen, A.Z.; Schultz, N.A.; Hansen, C.P.; Hasselby, J.P.; Holländer, N.H.; Nissen, M.H.B.; Bjerregaard, J.K.; et al. Identification of New Biomarkers in Patients with Pancreatic Cancer (BIOPAC): A Study Protocol of an Open Cohort Study. J. Cancer Sci. Ther. 2019, 11, 232–239. [Google Scholar]
- Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 1987, 40, 373–383. [Google Scholar] [CrossRef]
- Ueno, H.; Okada, S.; Okusaka, T.; Ikeda, M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000, 59, 296–301. [Google Scholar] [CrossRef] [PubMed]
- Kjaergaard, A.D.; Bojesen, S.E.; Nordestgaard, B.G.; Johansen, J.S. YKL-40 and alcoholic liver and pancreas damage and disease in 86,258 individuals from the general population: Cohort and mendelian randomization studies. Clin. Chem. 2014, 60, 1429–1440. [Google Scholar] [CrossRef] [Green Version]
- Bartlett, J.W.; Seaman, S.R.; White, I.R.; Carpenter, J.R.; Alzheimer’s Disease Neuroimaging, I. Multiple imputation of covariates by fully conditional specification: Accommodating the substantive model. Stat. Methods Med. Res. 2015, 24, 462–487. [Google Scholar] [CrossRef]
- Chen, Y.; Zhang, S.; Wang, Q.; Zhang, X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J. Hematol. Oncol. 2017, 10, 36. [Google Scholar] [CrossRef] [Green Version]
- Cohen, N.; Shani, O.; Raz, Y.; Sharon, Y.; Hoffman, D.; Abramovitz, L.; Erez, N. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene 2017, 36, 4457–4468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dimitrakopoulos, C.; Vrugt, B.; Flury, R.; Schraml, P.; Knippschild, U.; Wild, P.; Hoerstrup, S.; Henne-Bruns, D.; Wuerl, P.; Graf, R.; et al. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants. JAMA Surg. 2019, 154, e190484. [Google Scholar] [CrossRef] [PubMed]
- Geng, B.; Pan, J.; Zhao, T.; Ji, J.; Zhang, C.; Che, Y.; Yang, J.; Shi, H.; Li, J.; Zhou, H.; et al. Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through beta-catenin/Erk/Akt signaling in gastric cancer. J. Exp. Clin. Cancer Res. 2018, 37, 208. [Google Scholar] [CrossRef] [PubMed]
- Huang, W.S.; Lin, H.Y.; Yeh, C.B.; Chen, L.Y.; Chou, Y.E.; Yang, S.F.; Liu, Y.F. Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan. Int. J. Med. Sci. 2017, 14, 136–142. [Google Scholar] [CrossRef] [Green Version]
- Kim, D.H.; Park, H.J.; Lim, S.; Koo, J.H.; Lee, H.G.; Choi, J.O.; Oh, J.H.; Ha, S.J.; Kang, M.J.; Lee, C.M.; et al. Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis. Nat. Commun. 2018, 9, 503. [Google Scholar] [CrossRef]
- Lee, C.G.; Da Silva, C.A.; Dela Cruz, C.S.; Ahangari, F.; Ma, B.; Kang, M.J.; He, C.H.; Takyar, S.; Elias, J.A. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 2011, 73, 479–501. [Google Scholar] [CrossRef] [Green Version]
- Libreros, S.; Iragavarapu-Charyulu, V. YKL-40/CHI3L1 drives inflammation on the road of tumor progression. J. Leukoc. Biol. 2015, 98, 931–936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ngernyuang, N.; Yan, W.; Schwartz, L.M.; Oh, D.; Liu, Y.B.; Chen, H.; Shao, R. A Heparin Binding Motif Rich in Arginine and Lysine is the Functional Domain of YKL-40. Neoplasia 2018, 20, 182–192. [Google Scholar] [CrossRef]
- Shao, R.; Taylor, S.L.; Oh, D.S.; Schwartz, L.M. Vascular heterogeneity and targeting: The role of YKL-40 in glioblastoma vascularization. Oncotarget 2015, 6, 40507–40518. [Google Scholar] [CrossRef] [Green Version]
- Yeo, I.J.; Lee, C.K.; Han, S.B.; Yun, J.; Hong, J.T. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol. Ther. 2019, 203, 107394. [Google Scholar] [CrossRef] [PubMed]
- Zhao, T.; Su, Z.; Li, Y.; Zhang, X.; You, Q. Chitinase-3 like-protein-1 function and its role in diseases. Signal. Transduct. Target. Ther. 2020, 5, 201. [Google Scholar] [CrossRef]
- Benn, M.; Nordestgaard, B.G.; Jensen, G.B.; Tybjaerg-Hansen, A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: The Copenhagen City Heart Study. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 661–670. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, H.S.; Lee, H.S.; Park, J.S.; Park, J.S.; Lee, D.K.; Lee, S.J.; Yoon, D.S.; Lee, M.G.; Jeung, H.C. Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res. Treat. 2016, 48, 1253–1263. [Google Scholar] [CrossRef] [Green Version]
- Salmiheimo, A.; Mustonen, H.; Stenman, U.H.; Puolakkainen, P.; Kemppainen, E.; Seppanen, H.; Haglund, C. Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. PLoS ONE 2016, 11, e0163064. [Google Scholar] [CrossRef]
- Tempero, M.A.; Uchida, E.; Takasaki, H.; Burnett, D.A.; Steplewski, Z.; Pour, P.M. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987, 47, 5501–5503. [Google Scholar]
Patient Characteristics | All | ≤1 Year Survival | >1 Year Survival | Missing, % |
---|---|---|---|---|
Number of participants, N (%) | 993 (100%) | 603 (61%) | 390 (39%) | NA |
Age, years | 67 (61–72) | 67 (61–73) | 67 (61–72) | 0 |
Women, % | 45 | 44 | 48 | 0 |
Eversmoker, % | 61 | 61 | 62 | 10 |
Body mass index, kg/m2 | 23.1 (20.7–25.8) | 23.2 (20.7–25.9) | 22.8 (20.7–25.7) | 5.8 |
High alcohol consumption, % | 23 | 22 | 23 | 10 |
Performance status | 1 (0–1) | 1 (0–1) | 0 (0–1) | 9.7 |
Charlson comorbidity index | 3 (2–4) | 3 (2–4) | 3 (2–4) | 3.7 |
Diabetes, % | 26 | 26 | 25 | 1.8 |
Operated, % | 30 | 16 | 52 | 0 |
Metastasing cancer, % | 50 | 65 | 27 | 0.5 |
Tumour size, mm | 3.5 (2.5–4.8) | 4.0 (3.0–5.0) | 3.0 (2.3–4.0) | 13 |
Stage I–II, % | 21 | 9.6 | 39 | 1.5 |
Stage III, % | 27 | 23 | 34 | 0.8 |
Stage IV, % | 51 | 66 | 27 | 0 |
C-reactive protein, mg/L | 9 (3–37) | 17 (5–52) | 4 (3–11) | 1.8 |
CA 19-9, kU/L | 445 (59–3126) | 997 (148–6290) | 105 (29–796) | 1.6 |
Interleukin-6, µg/L | 5.4 (2.7–12) | 7.2 (3.9–16) | 3.3 (2.0–6.1) | 0 |
YKL-40, µg/L | 138 (81–227) | 156 (92–246) | 113 (67–205) | 0 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kjaergaard, A.D.; Chen, I.M.; Johansen, A.Z.; Nordestgaard, B.G.; Bojesen, S.E.; Johansen, J.S. Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer. Cancers 2021, 13, 4599. https://doi.org/10.3390/cancers13184599
Kjaergaard AD, Chen IM, Johansen AZ, Nordestgaard BG, Bojesen SE, Johansen JS. Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer. Cancers. 2021; 13(18):4599. https://doi.org/10.3390/cancers13184599
Chicago/Turabian StyleKjaergaard, Alisa D., Inna M. Chen, Astrid Z. Johansen, Børge G. Nordestgaard, Stig E. Bojesen, and Julia S. Johansen. 2021. "Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer" Cancers 13, no. 18: 4599. https://doi.org/10.3390/cancers13184599